Today: 5 February 2026
Subscribe
Browse Category

NASDAQ:PCSA News 18 December 2025

Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

December 18, 2025 — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is back on traders’ radar after the company reported fresh clinical observations from its Phase 2 breast cancer program and implemented another reverse stock split to consolidate shares. The result: a whiplash week for the stock, a surge in attention, and a new set of near-term catalysts that now matter more…
18 December 2025
····

Stock Market Today

  • Coherent (COHR) Valuation Debated Amid Recent Stock Price Swings
    February 5, 2026, 12:44 PM EST. Coherent (COHR) saw its shares close at $211, marking a 7.9% drop in one day despite strong gains of 13.2% over one month and 32.5% over three months. Over the past year, its total shareholder return hit 134.2%, signaling sustained momentum. The stock trades slightly above its analyst price target of $203.47 and a fair value estimate of $192.95, suggesting possible overvaluation. Growth is driven by demand for advanced optical components supporting AI datacenter infrastructure and high-performance computing. However, risks remain, including pricing pressure from low-cost competitors and potential order reductions from key clients like Apple. Investors should weigh these drivers and risks carefully and consider broader market alternatives for a balanced view.
Go toTop